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E-mail: j.h.e.kuball@umcutrecht.nlT cell engineering strategies offer cures to patients and have
entered clinical practice with chimeric antibody-based recep-
tors; abT cell receptor (abTCR)-based strategies are, however,
lagging behind. To allow a more rapid and successful transla-
tion to successful concepts also using abTCRs for engineering,
incorporating a method for the purification of genetically
modified T cells, as well as engineered T cell deletion after
transfer into patients, could be beneficial. This would allow
increased efficacy, reduced potential side effects, and improved
safety of newly to-be-tested lead structures. By characterizing
the antigen-binding interface of a good manufacturing process
(GMP)-grade anti-abTCR antibody, usually used for depletion
of abT cells from stem cell transplantation products, we devel-
oped a strategy that allows for the purification of untouched
abTCR-engineered immune cells by changing 2 amino acids
only in the TCRb chain constant domain of introduced TCR
chains. Alternatively, we engineered an antibody that targets
an extended mutated interface of 9 amino acids in the TCRb
chain constant domain and provides the opportunity to further
develop depletion strategies of engineered immune cells.
INTRODUCTION
The US Food and Drug Administration (FDA) approval of the first
engineered T cells expressing chimeric antigen receptors (CARs)
has paved the way for new cellular interventions in the clinic.1,2 A
next wave of cell therapy will come with T cell receptor (TCR)-engi-
neered T cells specific for targets on both solid and hematological ma-
lignancies.3 Most clinical trials using abTCR-engineered T cells are
directed against cancer/testis antigens, such as NY-ESO-1.4 Although
the clinical response rates are very encouraging, only a small propor-
tion of the patients benefit from these novel treatments.5,6 Disap-
pointing response rates can be partially attributed to the presence
of non-engineered and poorly engineered T cells in the administered
cell product.7 These non-engineered and poorly engineered T cells
can hamper the therapeutic efficiency of engineered immune effector
cells because of, e.g., insufficient expression of the introduced recep-388 Molecular Therapy: Methods & Clinical Development Vol. 22 Septe
This is an open access article under the CC BY license (http://creatitor, mispairing of introduced abTCR with endogenous abTCR,8 or
by competition for endogenous homeostatic cytokines.7,9 Further-
more, in an allogenic setting, the presence of T cells still expressing
the endogenous abTCR can lead to severe graft-versus-host disease.
Purification of engineered T cells before infusion can overcome these
hurdles, ultimately resulting in enhanced in vivo activity. Current
methods for purification of engineered T cells often depend on the
expression of artificial molecules such as truncated CD3410 or trun-
cated NGFR,11 in addition to the tumor-specific receptor. However,
larger transgene cassettes used to introduce multiple proteins are rela-
tively difficult to express, and additional transgenes can add immuno-
genic properties to the engineered cell product.12 Besides purification
of engineered T cells to increase effectivity, elimination of engineered
T cells after adoptive transfer might be needed in case of cytokine
release syndrome13 or off-target toxicities, e.g., due to peptide mim-
icry,5,14 expression of the antigen at low levels in healthy tissues,14
ormispairing of introduced with endogenous abTCR chains resulting
in unwanted specificities.8 A currently explored solution for the elim-
ination of transferred cells is the co-expression of herpes simplex
virus thymidine kinase (HSV-TK) along with the transgene of inter-
est,15 mainly limited by the immunogenicity and relatively large size
of the HSV-TK gene.15 An alternative elegant solution is to introduce
a myc-tag into the abTCR sequence itself, followed by in vivo deple-
tion through myc-specific antibodies.16 However, introducing
artificial genes into the abTCR might alter downstream signaling
by modifying, e.g., its glycosylation.17 Selection of engineered
T cells and subsequent in vivo elimination achieved with a single
marker, which has previously been described for CD20,18 would be
favorable, due to the relatively small transgene cassette and thereforember 2021 ª 2021 The Author(s).
vecommons.org/licenses/by/4.0/).
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duced tumor-specific TCR could also be used for both purification
and in vivo depletion, and thereby would combine all three properties
in one gene: tumor specificity, a selection opportunity of cells express-
ing the transgene at high levels, as well as an in vivo depletion option,
which allows for the elimination of the engineered immune cells in
case of toxicities caused by the introduced receptor. Within this
context we have explored a strategy based on the recent development
of purified T cells engineered to express a defined gd T cell receptor
(TEGs).19–29 In this strategy we took advantage of the observation
that an anti-human abTCR antibody used for the purification of
TEGs does not cross-react with gdTCR chains, and it can thereby
differentiate between engineered and non-engineered cells. This
anti-human abTCR antibody is routinely used to deplete abTCR
T cells from apheresis products using CliniMACS depletion before
allogeneic stem cell transplantation.3,28 In this study, we describe
the translation of the TEG purification procedure into a purification
procedure for abTCR-engineered T cells. We also provide the ratio-
nale for the additional development of elimination strategies of engi-
neered immune cells by further modulating the binding site to be
selectively targeted by a second independent antibody.
RESULTS
Anti-human abTCR binds an epitope on the TCRb chain of
human abT cells
The good manufacturing practice (GMP)-grade anti-human abTCR
monoclonal antibody clone BW242/412 (from now on referred to as
anti-human abTCR) recognizes a common determinant of the hu-
man TCRa/b-CD3 complex, which has not yet been characterized.
In order to allow for further epitope mapping of the interface between
the anti-human abTCR clone BW242/412 and a human abTCR, we
first tested the antibody’s ability to bind to murine abTCRs. There-
fore, Jurma T cells, a TCR-deficient T cell line, were transduced
with human abTCRs directed against the cancer/testis antigen NY-
ESO-1157–165
29 or with a murine nonsense abTCR composed of the
TCRa chain of an MDM2-specific abTCR,30 and the TCRb chain
of a p53-specific abTCR.31 Specific binding of the anti-human
abTCR was only observed in the human (aHuHu/bHuHu) but not
the murine (aMuMu/bMuMu) TCR-transduced Jurma cells (Fig-
ure 1A). To rule out that parts of the human variable domain of
the abTCR bind to the anti-human abTCR antibody, the human
NY-ESO-1 abTCR variable domain was grafted on the murine con-
stant domain to create a chimeric abTCR (aHuMu/bHuMu). Replac-
ing only the human TCRa and TCRb constant domains by murine
equivalents completely abrogated binding of anti-human abTCR to
levels resembling binding to a fully murine abTCR (aMuMu/
bMuMu). This indicates that the human constant domain contains
the binding epitope. Comparable transgenic expression of murine
and human TCRs was confirmed by anti-MuTCRb and anti-Vb4,
respectively (Figure 1A). Infusion of T cells expressing TCRs with
complete murine constant domains into patients can generate immu-
nogenic effects and lead to a decreased persistence of the engineered
cells in vivo.32 To minimize these undesirable effects, we aimed to
map the minimal amount of murine residues needed to disrupt bind-Molecular Theing of anti-human abTCR by making use of previously described
chimeric TCRa and b chains, with mutational blocks covering all
amino acid (aa) differences between the constant regions of human
and mouse abTCRs.29 We tested three NY-ESO-1 TCRa chain vari-
ants and four NY-ESO-1 TCRb chain variants, with each containing
one murine domain, flanked by complete human aa sequences. Every
TCRa chain was paired with the fully human TCRb chain (bHuHu)
(Figure 1B), and every TCRb chain was paired with the fully human
TCRa chain (aHuHu) (Figure 1C) and introduced into Jurma cells,
after which binding of anti-human abTCR was determined by flow
cytometry. Antibody binding was significantly impaired in T cells ex-
pressing the abTCR, which includes murine domain 3 (bHuM3),
while none of the other chimeric abTCRs substantially impaired
anti-human abTCR binding (Figures 1B and 1C). bHuM3 TCR
expression was confirmed by staining for anti-Vb4 and was compara-
ble to aHuHu/bHuHu (Figure S1). These results indicate that domain
3 of the TCRb chain (bHuM3) dictates the binding of anti-human
abTCR.
Anti-human abTCR binding can be abrogated by mutating two
residues
Analysis of the sequence of domain 3 of the TCRb chain constant
domain revealed 11 residues that are non-homologous between mu-
rine and human species (Figure S2). To determine which residues are
essential for anti-human abTCR binding, we constructed 11 variants
of the TCRb chain, in which each one of the non-homologous aas
was replaced by the murine counterpart. These 11 constructs were
paired with the completely human aTCR chain (aHuHu), intro-
duced in Jurma cells and tested for binding by the anti-human
abTCR antibody. Of the 11 generated mutants, the substitutions of
“human” glutamic acid (E108) to the “murine lysine” (K), “human”
threonine (T110) to the “murine” proline (P), and “human” aspartic
acid (D112) to the “murine” glycine (G) showed a substantial abro-
gation of anti-human abTCR binding (Figure 2A). However, none of
these substitutions was sufficient to induce total abrogation, as
shown by the TCR consisting of aHuHu/bHuM3 (Figure 2A).
Therefore, we constructed TCRb chains with a combination of the
aforementioned mutations. The TCRb chains with a D112G muta-
tion combined with E108K or T110P were both effective in abro-
gating binding of the anti-human abTCR antibody (Figure 2B),
which can be explained by a substantial decrease in bulkiness, and
thus a decrease in size of these residues (Figure 2C; Table S1). For
further engineered T cell experiments, the combination of T110P
and D112G murinization was selected.
Enrichment of abTCR-engineered T cells utilizing fragments of
murine abTCR chains
Murine abTCRs, or residues derived from murine abTCRs intro-
duced into human abTCRs and expressed in human T cells, have
been reported to outcompete endogenous human TCR chains.29,33,34
These murine and murinized abTCRs preferentially pair with each
other, thereby decreasing the occurrence of mispairing with endog-
enous human abTCRs. Therefore, we utilized single murine aas to
enhance the expression of introduced TCRs.29 These “minimallyrapy: Methods & Clinical Development Vol. 22 September 2021 389
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Figure 1. Partial murinization of the TCRb chain
constant domain abrogates binding of the anti-
human abTCR antibody clone BW242/412
(A) Jurma cells were transduced with fully murine (aMuMu/
bMuMu), fully human NY-ESO-1-specific (aHuHu/bHuHu)
or chimeric abTCR, in which the a and b constant domains
were murine, and the variable domains were human NY-
ESO-1 specific. Binding of anti-human abTCR, anti-
MuTCRb, and Vb4 was assessed by flow cytometry. (B
and C) Schematic representation of the constructed vari-
able (V) and constant (C) domains of abTCRs that cover all
aa differences in the (B) TCRa chain and (C) TCRb chain
(upper panels). The constant domain of the TCRa and b
chain have been divided in respectively three or four
different regions, based on the comparison of human and
murine regions revealing clustered differences flanked by
homologous regions as described.29 Jurma cells were
transduced with the different murinized abTCRs, after
which anti-human abTCR antibody binding was assessed
by flow cytometry. The bar graphs (B and C, lower panels)
show the anti-human abTCR MFI relative to the fully hu-
man TCR. Untransduced Jurma cells served as a negative
control. The data correspond to two independent experi-
ments, and a representative figure is shown (A) or as the
average with standard deviation (B and C).
Molecular Therapy: Methods & Clinical Developmentmurinized” constant domain variants (from now on referred to as
mm) contain murine aas that are both critical and sufficient to
improve pairing between the two chains.29 Next, we introduced
the above-identified murine residues (T110P+D112G) in the
TCRb chain constant domain in order to test whether this was suf-
ficient to disrupt the binding of anti-human abTCR in human pri-
mary T cells. To test this concept, healthy donor T cells were trans-
duced with mm NY-ESO-1-specific abTCRs as a negative control,
or mm NY-ESO-1-specific abTCRs, including the two identified
mutations T110P+D112G. Magnetic-activated cell sorting (MACS)390 Molecular Therapy: Methods & Clinical Development Vol. 22 September 2021depletion using anti-human abTCR resulted
in an increased cell fraction not able to bind
anti-human abTCR after an expansion of
2 weeks, in order to assess stability of the
phenotype (Figure 3A). However, we also
observed outgrowth of a large fraction of
Vb4- and abTCR-negative cells, mainly con-
sisting of natural killer (NK) and gd T cells,
as reported previously.20 To further increase
purity of engineered immune cells, T cells
were selected by CD4/CD8 MACS from periph-
eral blood mononuclear cells (PBMCs) prior to
the transduction. This indeed prevented the
outgrowth of NK and gd T cells after abTCR
depletion and expansion (Figure 3B). Next, we
quantified the fraction of NY-ESO-1157–165
HLA*02:01 pentamer+ cells before and after
depletion, showing a significant increase in
pentamer+ cells after depletion (Figure 3C),further proving successful enrichment of engineered immune cells
when using T110P+D112G-modified abTCRs.
Enrichment strategy within the context of alternative abTCR
stabilization procedures
Multiple alternative strategies to prevent abTCR chain mispairing and
thereby increase the expression of the introduced tumor specific
abTCRhave been reported. For example, adding an additional cysteine
residue to introduce a disulfide bridge between the a and b chains has




Figure 2. A combination of 2 specificmurine aa in the
TCRb chain constant domain is sufficient to
abrogate binding of the anti-human abTCR antibody
clone BW242/412
(A) Jurma cells were transduced with abTCRs containing
single murine aa substitutions in the third domain of the b
chain, after which binding of the anti-human abTCR anti-
body was assessed using flow cytometry. Untransduced
Jurma cells served as a negative control, while fully human
abTCR-transduced Jurma cells served as a positive con-
trol. (B) Jurma cells were transduced with abTCRs con-
taining combinations of murine aas in the third domain of
the b chain, after which binding of anti-human abTCR
antibody was assessed using flow cytometry. (C) Visuali-
zation of the 11 non-homologous aa between human and
mouse b chain third domain in cyan using SWISS-
MODEL52 on the modeled template of the b chain of the
human JKF6 T cell receptor (PDB: 4ZDH). Effective single
murine aa substitutions are displayed in red. The data
correspond to one experiment (A) or two independent
experiments shown with a representative image (B) and
average with standard deviation (B, bar graph).
www.moleculartherapy.orghuman gdTCRs introduced in human T cells do not pair with endog-
enous abTCRs.35 Therefore, it was attractive to use gdTCR transmem-
brane domains for engineering abT cells in a similar way. We tested
whether our enrichment strategy could also be combined with these
alternative pairing solutions. First, we constructed an NY-ESO-1-spe-
cificTCRwith anadditional disulfidebridge by themutationof one spe-
cific residue in each chain, i.e., T48C in TCRCa and S57C in TCRCb.8
Second, we constructed an NY-ESO-1-specific TCR with the same
additional disulfide bridge, and with a human gdTCR transmembraneMolecular Therapy: Methods & Clinidomain. These TCRs were compared to the
previously used mm TCR strategy (schematic
representation, Figure 4A). To later make use of
the abTCR depletion method, we introduced
the mutations T110P+D112G in the b chains.
We then assessed the expression of the different
TCRs in primary T cells by measuring the
percentage of Vb4+ and NY-ESO-1157-165
HLA*02:01 pentamer+ cells within theCD8+ pop-
ulation (Figure 4B). All three conditions resulted
in a NY-ESO-1157-165 HLA*02:01 pentamer
+
CD8+ fraction comparable in size to the Vb4+
CD8+ fraction, indicating that in all cases the
introduced TCR chains are preferentially paired
(Figures 4B and S3). Amodest, but significant, in-
crease in expression of the introduced TCR was
observed when using a combination of a cysteine
bridge and the gd-transmembrane domain when
compared to themm variant (Figure 4C). The in-
crease in expressionofVb4was associatedwith an
increase of the single Vb4+ cells to Vb4/endoge-
nous abTCR double-positive cells (Figure 4D),indicating that combination of the cysteine bridge and gd-transmem-
brane domain was most potent in the downregulation of the endoge-
nous abTCR. Next, the three different conditions were abTCR
depleted in the same way as before, and the percentage of Vb4+ cells
(Figure 5A) and NY-ESO-1157–165 HLA*02:01 pentamer
+ cells within
the CD8+ population (Figure 5B) was measured by flow cytometry,
showing successful enrichment for transduced cells in all conditions.
After depletion, however, we did not see significant differences in %
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ential pairing and subsequent purification by our abTCR depletion
method with a slight advantage of combination of the cysteine bridge
and gd-transmembrane domain when assessed by TCR expression.
Augmented in vitro tumor cell recognition by purified engineered
T cells
To assess whether purified NY-ESO-1157–165 abTCR-engineered
T cells were superior in target cell recognition compared to non-pu-
rified cells, we pulsed T2 cells with multiple concentrations of NY-
ESO-1157–165 peptide. Purified engineered T cells showed a stronger
response to the peptide-loaded T2 cells than to the non-purified cells.
Furthermore, we observed that interferon (IFN)g release was associ-
ated with positivity for the different introduced TCRs (Figure 5C).
Purification also resulted in the improved recognition of endoge-
nously processed and presented peptide in the NY-ESO-1-positive
tumor cell lines Saos-2 and U226 when assessed by IFNg release (Fig-
ure 5D). As we observed varying and only minor differences between
the three strategies (Figures 4 and 5), and wanted to introduce as few
changes as possible in engineered TCRs, the mm approach was used
in the next set of experiments to prevent mispairing and increase
expression of the introduced TCR as reported.29 The placement of
these 9 murine aa, not on the surface but rather buried within the
TCR, makes it unlikely that they would cause immunogenicity of
the mm TCR as suggested by Sommermeyer et al.29
Developing an antibody recognizing the introduced mutated
region
The infusion of engineered T cells can potentially be toxic, due to the
occurrence of cytokine release syndrome13 or the off-target toxicity of
the receptor used.14 To be able to deplete infused engineered T cells
in vivo when deemed necessary, we first sought to raise an antibody
specific for the T110P+D112G murinized variant of the abTCR by
immunizing threeWistar rats with a human-mouse chimeric peptide.
Despite that antibodies were formed against the chimeric peptide
(Figure S4A), no antibody binding to surface-expressed abTCRs
could be detected (Figure S4B). Therefore, we assessed whether the
commercially available anti-murine TCRb chain antibody clone
H57-597 (from now on referred to as anti-MuTCRb) was able to
bind the murinized abTCRs on Jurkat-76 cells generated so far. Ju-
rkat-76 cells expressing the T110P+D112G murinized variant of the
abTCR (indicated by bHumm 2/11; i.e., 2 out of the 11 non-homol-
ogous aa in the third domain are murinized) were not bound by anti-
MuTCRb; however, Jurkat-76 cells expressing the bHummM3Figure 3. Primary abT cells engineered with murinized abTCRs can be succes
deplete non-engineered and poorly engineered immune cells
(A) PBMCs were transduced with minimally murinized abTCRs with (middle panel) and w
wereMACS depleted and expanded (right panel). Endogenous abTCR expression and e
flow cytometry using an anti-human abTCR antibody; expression of the introduced b
minimally murinized abTCRs, T cells were selected from PBMCs using CD4/CD8 MAC
sessed before and after depletion and expansion by NY-ESO-1 pentamers (CD8+) for
experiments and are shown as a representative figure (A and B) or as average with standa
a paired t test.
Molecular Themurinized variant of the abTCR (indicated by bHumm 11/11; i.e.,
all 11 non-homologous aa in the third domain are murinized) were
bound by anti-MuTCRb (Figure 6A). To limit the amount of murine
aas introduced, we also constructed a variant in which 9 out of 11
non-homologous aa in the third domain are murinized
(Figure S4C). Both 11/11 and 9/11 non-homologous murine aa in
the b chain of domain 3 were sufficient to reestablish binding of
anti-MuTCRb, but not to the same extent as the HuMu abTCR (Fig-
ure 6A). Surprisingly, 9/11 caused a higher mean fluorescence inten-
sity (MFI) than did 11/11. Structural analyses suggested that this
differential binding could be a consequence of the fact that 9/11 con-
tains one less negatively charged residue and therefore results in a
more focused electrostatic potential to attract the lysine on CDR1
of anti-MuTCRb (Figure 6B). To confirm that the anti-MuTCRb
antibody binds to the Vb4+ cells, co-staining was performed with
both antibodies on transduced primary T cells. The MFI of anti-
MuTCRb-PE was plotted for the Vb4+ gated cells, which showed
that the anti-MuTCRb antibody bound best to the 9/11 or complete
murine constant domain (Figure 6C). As expected, there was no bind-
ing to the 2/11 variant but surprisingly also not to the 11/11 variant.
This might suggest some interference when both antibodies are used
in a co-staining, mainly affecting the suboptimal anti-muTCRb bind-
ing to the 11/11 variant.
Since the clone of anti-MuTCRb antibody is of Armenian hamster
origin and presumably induces severe side effects once administered
to humans, comparable to anti-thymocyte globulin,36 we aimed to
generate a humanized variant of anti-MuTCRb.Wegenerated chimeric
variants of anti-MuTCRb (H57-597, PDB: 1NFD) by exchanging the
hamster immunoglobulin (Ig)G2 constant domain for the human
IgG1 constant domain (referred to as chimeric anti-MuTCRb). We
tested binding of this newly constructed antibody in engineered Ju-
rkat-76 cells, which resulted in specific antibody binding to the 9/11
murinized TCRb chain expressed on Jurkat-76 cells (Figure S5). To
determine the capacity of the chimeric anti-MuTCRb antibody to
bind to primary T cells expressing the murinized abTCRs, we conju-
gated this antibody and an isotype control to Alexa Fluor 488
(AF488) and determined binding by flow cytometry. The chimeric
anti-MuTCRb antibody was able to bind both 9/11 and 11/11 muri-
nized TCRs and, as shown in Figure 6A, the binding to 9/11 was stron-
ger than to 11/11 (Figure 6D). To assesswhether the chimeric variant of
anti-MuTCRbwas able to selectively deplete engineered T cells in vitro,
the antibody was coupled to monomethyl auristatin E (MMAE), a cell
cycle inhibitor, using the protease cleavable linker VC-PAB37 to createsfully selected by using anti-human abTCR antibody clone BW242/412 to
ithout (left panel) the “TPDG” mutations. Primary abT cells with the TPDGmutations
xpression of the introduced abTCRwithout the TPDGmutations were determined by
TCR chain was assessed with an anti-Vb4 antibody. (B) Prior to transduction with
S selection (CD4/CD8+). (C) Expression of correctly paired abTCR chains was as-
both transduction strategies combined. The data correspond to three independent
rd deviation (C). Statistical significance (*p% 0.05, **p% 0.01) was calculated using
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differentmurinizedTCRswere incubatedwithmultiple concentrations
of theADC.The highest concentration of chimericH57-MC-VC-PAB-
MMAE led to a decrease of Vb4 positivity in the 9/11 condition only
(Figure 6E). This specific decrease indicated that the ADC is able to
selectively deplete 9/11, and not 11/11, abTCR-engineered Jurkat-76
in vitro, most likely due to the weaker binding of the engineered anti-
body to the 11/11 abTCR (Figure 6D). However, depletion was far
from complete, indicating that although this binding site is interesting,
it is far from being developed for a kill strategy.
DISCUSSION
The main finding of our study is that replacing only 2 aa within the
constant domain of the TCRb chain allows for the purification of
abTCR-engineered T cells with GMP-ready tools,38 without the
need for additional complex genetic engineering. The very same
region on the TCRb chain can also serve as a targeting interface for
antibodies, which can be used to develop strategies to eliminate engi-
neered immune cells. These new insights provide the molecular basis
for developing select-kill strategies for increasing purity and aug-
menting the safety of abTCR engineered T cells, with only minor en-
gineering steps.
A sufficient downregulation of the endogenous abTCR chains by the
introduced abTCR chains is essential for this method to work. There-
fore, strategies interfering with endogenous abTCRs or utilizing
knockout of the a or b locus to enhance expression of introduced
abTCRs39 will benefit from this strategy. However, engineering
T cells via zinc finger nucleases (ZFNs), CRISPR, or transcription
activator-like effector nucleases (TALENs)40 requires additional engi-
neering steps and therefore is an additional hurdle for GMP-grade pro-
duction. We accomplished dominance of the introduced receptors by
using a previously described method where human residues are re-
placed by key murine counterparts.29 Furthermore, we successfully as-
sessedwhether the introduction of an additional disulfide bridge8 or the
exchange of the humanabTCR transmembrane domain for the human
gdTCR counterpart19 could also lead to enhanced expression. Thus, we
found, in line with our recently published solution for TEGs,19 an
elegant and minimalistic strategy to purify abTCR-engineered T cells.
We observed, as reported previously for purification of TEGs,19,20
that abT cells double positive for endogenous and introduced
TCRs are also depleted. This is most likely due to the high affinity
of the GMP-grade depletion antibody to the natural bTCR chain.
This resulted in a substantial loss of engineered immune cells with re-
sidual endogenous abTCR expression. Although the purified popula-Figure 4. Efficacy of different strategies to induce preferential pairing of introd
(A) Schematic representation of the three different methods for creating preferential pairin
variable domain; C, constant domain. (B) Primary abT cells were transduced with the thre
bTCR was determined by an anti-Vb4 antibody. (C and D) Pairing of the introduced aTC
Vb4+ cells was quantified for the differently modified abTCR (D) ratio between Vb4 single
two independent experiments and are shown as a representative figure (B) or as the aver
was calculated using a one-way ANOVA.
Molecular Thetion represented only a small fraction of the initial population, we
have shown when using this process for gdTCRs engineered immune
cells that the recovery is sufficient to reach therapeutic cell numbers in
a full GMP-grade process.20 Furthermore, we observed enrichment of
NK and gdT cells after depletion, previously reported for gdTCR-en-
gineered immune cells20 and transplantation products41 as well.
Therefore, selection of CD4+ and CD8+ T cells prior to transduction
is recommended when applying our strategy. Selection of CD4+ and
CD8+ T cells is used already successfully during the full grade GMP
production process of approved CAR T products.42 Overall, our strat-
egy can further improve the current practice for infused engineered
products that harbor only between 15% and 55% engineered immune
cells,43,44 since the lack of purity of infusion products can become a
major clinical obstacle in terms of efficacy19 as well as toxicity.13,45
Many tumor-associated antigens targeted by abTCR gene therapy are
not exclusively expressed on tumor cells.46 Thus, depending on the type
of antigen targeted by the introduced abTCR, depletion strategies can
be useful. This is illustrated bymultiple clinical trials, which have led to
devastating results caused by off-target or on-target but off-tumor tox-
icities.5,14 Preclinical strategies topredict off-target toxicities by affinity-
enhanced TCRs provide an important tool to minimize these risks.47
However, these strategies are not infallible, and therefore an additional
safeguard would be extremely valuable when, e.g., targeting novel anti-
gens or antigens that are also partially expressed on healthy tissues.
Methods described so far for introducing a safety switch in engineered
T cell products rely on the introduction of additional genes for the
expression of (truncated) targetable proteins, the introductionof induc-
ible caspase proteins,48 or sensitivity to ganciclovir in the case of the
widely used HSV-TK suicide gene.15 The strategy described herein, us-
ingminimalmurine aa substitutions, is not only suitable for creating an
untouched population of purified T cells, but it also has the potential to
develop strategies that will allow an in vivo depletion when needed.
However, to accomplish this goal, the two identified murine aas that
enable abTCR depletion needed to be expanded with an additional 7
aa to create a chimeric TCRb chain with a total of 9murine aa. Thema-
jor advantage of our strategy, as compared to strategies using, e.g., myc-
tags introduced into the TCRa chain,16would be its combined property
as a selection and a safeguard system, aswell as its use of naturalabTCR
domains, which most likely do not affect signaling or impair pairing.
However, a major remaining limitation of our approach at this stage
is the reduced binding efficacy of our engineered depletion antibody
to the murine mutants when compared to the murine wild-type,
implying that further engineering of the TCR domain or affinity matu-
ration of the antibody will be needed to enable translation of this strat-
egy into an efficient killing strategy in vivo. As binding of the antibody isuced aTCR and bTCR chains
g between the introduced aTCR and bTCR chains. TM, transmembrane domain; V,
e differentially modified abTCRs as indicated in (A), and expression of the introduced
R and bTCR chains was assessed by NY-ESO-1 pentamers (C), and the percentage
-positive/Vb4/abTCR double-positive cells was determined. The data correspond to
age with standard deviation (C and D). Statistical significance (*p% 0.05, **p% 0.01)




Figure 5. Depletion of non-engineered and poorly
engineered T cells within the context of different
preferential abTCR pairing strategies
Primary abT cells were transduced with the three differ-
ently modified abTCRs as indicated in Figure 4A and
depleted with the anti-human abTCR antibody clone
BW242/412. (A) Directly before and after depletion,
expression of the introduced bTCR was determined by an
anti-Vb4 antibody. (B) Expression of appropriately paired
introduced aTCR and bTCR chains was determined by
NY-ESO-1 pentamers. (C and D) Functionality of purified
or non-purified engineered immune cells was assessed in
a stimulation assay after co-incubation with NY-ESO-
1157–165 peptide-pulsed T2 cells (C) or tumor cell lines with
endogenous expression of NY-ESO peptide (D). IFNg
production was measured in the supernatant by ELISA.
The data correspond to three (A and B) or two (C and D)
independent experiments and are shown as average with
standard deviation (A and B) or a representative figure (C
and D). Statistical significance (*p% 0.05, **p% 0.01) was
calculated using a one-tailed paired t test.
Molecular Therapy: Methods & Clinical Developmentalso partially driven by residues in the Cb-TCR M1 domain,49 addi-
tional introduction of severalmurine aas in this domain could therefore
be considered.
In conclusion, the murinization of two specific residues in the TCRb
constant domain allows for the untouched isolation of abTCR-engi-
neered T cell products, and it can be easily introduced in existing
GMP procedures. When a safeguard of engineered immune cells is
required, mutating an additional 7 human aa to murine residues in
the TCRb constant domain allows for binding of an antibody, which
has the potential to, after further optimization, selectively recognize
engineered T cells. However, the second step will require additional396 Molecular Therapy: Methods & Clinical Development Vol. 22 September 2021engineering of the TCR-antibody interface as
well as carefully selecting the appropriate killing
mechanism to reach its full potential.
MATERIALS AND METHODS
Cells and cell lines
Phoenix-Ampho cells (CRL-3213) were ob-
tained from ATCC and cultured in DMEM
(Thermo Fisher Scientific, Breda, the Netherl
ands) containing 1% penicillin/streptomycin
(Pen/Strep) (Invitrogen by Thermo Scientific,
Breda, the Netherlands) and 10% fetal calf serum
(FCS) (Bodinco, Alkmaar, theNetherlands). The
TCRb/ Jurma cell line (a derivate of Jurkat
J.RT3-T3.5 cells50), a kind gift from Erik Hooij-
berg (VU Medical Center, Amsterdam, the
Netherlands), TCRb/ Jurkat-76, a kind gift
from Miriam Heemskerk (LUMC, Leiden,
the Netherlands), and the T2 cell line (ATCC
CRL-1992) were cultured in RPMI 1640 +Gluta-
MAX (Thermo Fisher Scientific, Breda, theNetherlands) containing 1% Pen/Strep and 10% FCS. Cell lines were
authenticated by short tandem repeat profiling/karyotyping/isoen-
zyme analysis. All cells were passaged for a maximum of 2 months, af-
ter which new seed stocks were thawed for experimental use. In addi-
tion, all cell lines were routinely verified by growth rate, morphology,
and/or flow cytometry and tested negative for mycoplasma using a
MycoAlert mycoplasma kit (Lonza, Breda, the Netherlands). PBMCs
were obtained from Sanquin Blood Bank (Amsterdam, the
Netherlands) and isolated by Ficoll-Paque (GE Healthcare, Eind-
hoven, theNetherlands) from buffy coats. PBMCswere cultured using
the previously described rapid expansion protocol (REP)35 in RPMI




Figure 6. Opportunities for depletion of engineered
T cells by using a mutation-specific antibody
(A) Jurkat-76 cells were transduced with five different
murinized abTCRs to assess binding of anti-MuTCRb.
Wild-type (WT) abTCR-transduced Jurkat-76 cells served
as a negative control, while Jurkat-76 cells transduced
with a TCR containing a complete murine constant
domain served as a positive control. (B) The structure of
the murinized constant domains (bHumm 11/11 and
bHumm 9/11) when binding of H57-597 was modeled on
the template of the b chain of the murine N15 T cell re-
ceptor (PDB: 1NFD).49 (C) Primary abT cells were trans-
duced with the five different murinized abTCRs, and co-
staining was performed with anti-MuTCR and anti Vb4
antibodies. Cells were first gated for Vb4 positivity, and
plots of the anti-MuTCR MFI in the Vb4-positive gate are
shown. (D) Primary abT cells expressing three different
murinized abTCRs were used to assess binding of wild-
type and chimeric anti-MuTCRb. Anti-Vb4 and anti-hu-
man IgG1-AF488 isotype were included as a positive and
a negative control, respectively. (E) Jurkat-76 expressing
four different murinized abTCRs were incubated with
chimeric H57-MC-VC-PAB-MMAE for 24 h and then
stained with an anti-Vb4 antibody. The data correspond to
one experiment (C), two independent experiments (D and
E) for which a representative figure is shown, or three in-
dependent experiments (A) shown in a bar graph repre-
senting average and standard deviation.
www.moleculartherapy.orgAmsterdam, the Netherlands), 1% Pen/Strep (Invitrogen by Thermo
Scientific, Breda, theNetherlands), and 50mMGibcob-mercaptoetha-
nol (Fisher Scientific, Thermo Fisher Scientific, Breda, the
Netherlands) (collectively called HuRPMI).
Cloning of TCR chains into single retroviral vectors
The minimally murinized Va16.1 and Vb4.1 chains from an NY-
ESO1157–165/HLA*02-specific TCR, respectively named M2.2.3 and
M1.KA,4.1, were generated as previously described.29 Additional
partially murinized (regions or single residues) TCR chains were or-
dered from GeneArt (Life Technologies, Thermo Fisher Scientific,
Breda, the Netherlands) or constructed via mutagenesis PCR.
Cysteine-modified chains were designed as reported previously.8 Var-Molecular Therapy: Methods & Cliniiants of chimeric ab/gd TCRs were composed
using the IMGT database (http://www.imgt.
org). Sequences were codon optimized and or-
dered in an industrial resistance, gene-harboring
vector or as DNA strings (GeneArt Life Technol-
ogies, Thermo Fisher Scientific, Breda, the
Netherlands). DNA strings were processed using
the TA TOPO cloning kit (Thermo Fisher Scien-
tific, Breda, the Netherlands) and cloned into the
pCR2.1-TOPOvector, according to themanufac-
turer’s protocol. All TCR chains were cloned
separately into the retroviral vector pMP71 be-
tween the EcoRI and NotI restriction sites using
the indicated restriction enzymes and T4 DNAligase (all from New England Biolabs, Ipswich, MA, USA). Transfor-
mation of ligated constructs was performed in JM109 competent
E. coli (Promega, Leiden, the Netherlands), and subsequent plasmid
DNA isolation was conducted using NucleoBond PC500, according
to the manufacturer’s protocol (Macherey-Nagel, Düren, Germany).
Retroviral transduction of primary T cells and T cell lines
Phoenix-Ampho packaging cells were transfected using FuGENE-
HD (Promega, Leiden, the Netherlands) with env (pCOLT-GALV),
gagpol (pHIT60), and separate pMP71 constructs containing a or b
chains from a NY-ESO1157–165/HLA-A*02-specific TCR (isolated
from clone ThP251) kindly provided by Wolfgang Uckert,29 or con-
taining TCRg(G115)-T2A-TCRd(G115)LM1.19 PBMCs preactivatedcal Development Vol. 22 September 2021 397
Molecular Therapy: Methods & Clinical Developmentwith 50 IU/mL interleukin (IL)-2 (Proleukin, Novartis, Arnhem, the
Netherlands) and 30 ng/mL anti-CD3 (clone OKT-3, Miltenyi Biotec,
Bergisch Gladbach, Germany), CD4/CD8 T cells selected from
PBMCs with a REAlease CD4/CD8 (TIL) MicroBead kit (Miltentyi
Biotec, Bergisch Gladbach, Germany) preactivated with anti-CD3/
CD28 Dynabeads bead to a T cell ratio of 1:5 (Thermo Fisher
Scientific, Breda, the Netherlands), and 1.7  103 IU/mL MACS
GMP recombinant human IL-7 and 1.5  102 IU/mL MACS GMP
recombinant human IL-15 (Miltenyi Biotec, Bergisch Gladbach, Ger-
many), and Jurma or Jurkat-76 cells were transduced twice within
48 h with viral supernatant in six-well plates (4  106 cells/well) in
the presence of 50 IU/ml IL-2 (PBMCs only), 1.7  103 IU/ml IL-7,
1.5  102 IU/ml IL-15, and CD3/CD28 Dynabeads at a 1:5 bead-
to-T cell ratio (CD4/CD8-selected T cells only), and 6 mg/mL
Polybrene (all) (Sigma-Aldrich, Munich, Germany). After transduc-
tion, primary T cells were expanded by the addition of 50 mL/well
anti-CD3/CD28 Dynabeads (Thermo Fisher Scientific, Breda, the
Netherlands) and 50 IU/ml IL-2 or 1.7  103 IU/mL IL-7 or 1.5 
102 IU/mL IL-15.
Purification of engineered T cells by MACS depletion of poorly
engineered and non-engineered immune cells
Transduced primary T cells were incubated with biotin-labeled
anti-human abTCR antibody (clone BW242/412; Miltentyi Biotec,
Bergisch Gladbach, Germany), followed by incubation with an anti-
biotin antibody coupled to magnetic beads (anti-biotin MicroBeads;
MiltentyiBiotec, BergischGladbach,Germany).19Next, the cell suspen-
sion was applied to an LD column in a QuadroMACS separator.
abTCR+ T cells were depleted by MACS cell separation according to
the manufacturer’s protocol (Miltentyi Biotec, Bergisch Gladbach,
Germany).
In silico TCR modeling
The structure of different murinized constant domains was pre-
dicted using SWISS-MODEL52 on the modeled template of the b
chain of the human JKF6 T cell receptor (PDB: 4ZDH). The struc-
ture of the murinized constant domains when binding H57-597 was
modeled on the template of the b chain of the murine N15 T cell
receptor (PDB entry code: 1NFD).49 Structure visualizations were
performed using the PyMOL molecular graphics system (https://
pymol.org/2/).
Chimeric antibody production and purification
Hamster-human (IgG1) chimeric H57-597 antibody was generated us-
ing Lonza expression vectors (pEE14$4-kappaLC, pEE14$4-IgG1).53,54
The antibody was produced by transient transfection of HEK293F cells
with the heavy chain coding plasmid, the light chain coding plasmid,
and pAdVAntage (accession no. U47294; Promega, Leiden, the
Netherlands) using 293fectin transfection reagent (Invitrogen, Thermo
Scientific, Breda, the Netherlands) following the manufacturer’s in-
structions. Antibody-containing supernatant was harvested 4 days af-
ter transfection and purified by affinity chromatography using HiTrap
protein G HP antibody purification columns (GE Healthcare, Eind-
hoven, the Netherlands).398 Molecular Therapy: Methods & Clinical Development Vol. 22 SepteSequencing
DNA sequences of cloning intermediates and final constructs in
pMP71 were verified by barcode sequencing (BaseClear, Leiden,
the Netherlands). 75 mg of plasmid DNA and 25 pmol of primer
specific for the pCR2.1-TOPO vector or pMP71 vector were pre-
mixed in a total of 20 mL and sent to BaseClear for Sanger
sequencing.
Flow cytometry
Cells were stained with Vb4-fluorescein isothiocyanate (FITC)
(TRBV29-1, clone WJF24; Beckman Coulter, Brea, CA, USA),
abTCR-phycoerythrin (PE) (clone BW242/412; Miltentyi Biotec, Ber-
gisch Gladbach, Germany), CD3-Pacific Blue (PB) (clone UCHT1;
Becton Dickinson [BD]), CD4-PeCy7 (clone RPA-T4; eBioscience,
Thermo Fisher Scientific, Breda, the Netherlands), CD8-allophycocya-
nin (APC) (clone RPA-T8; BD), CD8-PB (clone SK1; BioLegend, San
Diego, CA, USA), or RPE-conjugated NY-ESO-1157–165 HLA*02:01
(SLLMWITQV) pentamer (ProImmune, Oxford, UK). Samples were
fixed using 1% paraformaldehyde (PFA) in PBS, measured on a FACS-
Canto II flow cytometer (BD, Eysins, Switzerland), and analyzed using
FACSDiva (BD, Eysins, Switzerland) or FlowJo (BD, Eysins,
Switzerland) software.
ELISA
Effector and target cells (E:T 50,000:50,000) were incubated for 16
h, after which supernatant was harvested. IFNg ELISA was per-
formed using an ELISA-ready-go! kit (eBioscience, Thermo Fisher
Scientific, Breda, the Netherlands) following the manufacturer’s
instructions.
MMAE ADC construction
Chimeric H57-MC-VC-PAB-MMAE was constructed using a kit
from CellMosaic (Woburn, MA, USA) following the manufacturer’s
instructions.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 8.3.0 for
Windows (GraphPad, La Jolla, CA, USA). Differences between
groups was calculated using a one- or two-tailed paired t test (Figures
3 and 5) or a repeated-measures one-way ANOVA (Figure 4). Normal
distribution of input data was assumed.
SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.
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